

(c) REMARKS

The claims are 21-34 with claims 21-24 being independent. Former claims 1-14 and 17-20 were cancelled in favor of new claims 21-34. Claims 21-24 correspond to former claims 17-20 rewritten in independent form. Dependent claims 25-34 correspond to former claims 5-14 rewritten to depend on either claim 23 or claim 24. Reconsideration of the claims is requested.

The objection to former claims 17-20 has been rendered moot by rewriting the claims to be in independent form.

The art rejection of former claims 1-14 has been rendered moot by cancellation of claims 1-4 and by making former claims 5-14 depend from new claims 23 and 24.

Applicants have reviewed the references applied against former claims 1-14 and believe none of them discloses the organic compounds of claims 21-24. Therefore, the former anticipation rejections are rendered moot.

In additional Ishida, JP '651 fails to disclose or suggest the instant monoaminofluorene compounds. The anthracene-substituted carbazole compounds of Ishida fail to render the instant monoaminofluorenes prima facie obvious.

Therefore, the present claimed invention is distinguished from the cited prior art compounds. Further, the defects of Ishida are not remedied by Xie, which fails to disclose or suggest the features missing in Ishida.

Wherefore, the claims should be allowed and the case passed to issue.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our address given below.

Respectfully submitted,

/Peter Saxon/
Peter Saxon
Attorney for Applicants
Registration No.: 24,947

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York 10112-3800
Facsimile: (212) 218-2200

FCHS_WS 3621648v1